Iovance Biotherapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

• Iovance Biotherapeutics Inc IOVA.OQ reported a quarterly adjusted loss of 26 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -45 cents. The mean expectation of fourteen analysts for the quarter was for a loss of 27 cents per share. Wall Street expected results to range from -36 cents to -23 cents per share.

• Revenue rose 15,189.2% to $73.69 million from a year ago; analysts expected $72.39 million.

• Iovance Biotherapeutics Inc's reported EPS for the quarter was a loss of 26 cents​.

• The company reported a quarterly loss of $78.56 million.

• Iovance Biotherapeutics Inc shares had fallen by 27.7% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 1.1% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Iovance Biotherapeutics Inc is $23.00

This summary was machine generated from LSEG data February 27 at 10:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)